Can gene therapies for haemophilia defend their high price tags?
Pharmaceutical Technology
NOVEMBER 9, 2022
CSL Behring has a commercialisation and license agreement to develop EtranaDez. million price tag. The post Can gene therapies for haemophilia defend their high price tags? A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96 million ($1.8 million at the time).
Let's personalize your content